| Open: | |
| Prev close: | |
| Range: | |
| Volume: |
| Bid: | |
| Bid volume: | |
| Offer: | |
| Offer volume: |
| Market cap: | 99,246,258,560 |
| EPS - TTM: | 1204.6 |
| P/E ratio: | 18.05 |
| Forward P/E: | 13.76 |
| Dividend yield: | 1.2 % |
| Last dividend: | 2.62ZAR |
| Date of last dividend: | 2021/09/01 |
| Return on equity: | 7.32 % |
| Return on assets: | 11.93 % |
| Net asset value: | 14,377.65 |
| Price/NAV: | 1.51 |
| Authorised shares: | 717,600,000 |
| Issued shares: | 456,451,541 |
Report |
Date |
|---|---|
| APN - Annual Report June 2021 | 2021/06/30 |
| APN - Annual Report June 2020 - Part 1 | 2020/06/30 |
| APN - Annual Report June 2020 - Part 2 | 2020/06/30 |
Sector: Pharmaceuticals and Biotechnology
'000 Rands |
Jun 21 F |
Dec 20 I |
|---|---|---|
| Turnover | 37,766 | 18,633 |
| Op Inc | 7,072 | 3,520 |
| Att Inc | 4,806 | 2,549 |
| Cash Gen PS | 1495.23 | 381.16 |
| Cshflo frm ops | 6,825 | 1,740 |
| Oper Pft Mgn | 18.73 % | 18.89 % |
'000 Rands |
Jun 21 F |
Dec 20 I |
|---|---|---|
| Fixed Ass | 14,826,000 | 14,336,000 |
| Tot Curr Ass | 32,643,000 | 43,449,000 |
| Ord SH Int | 65,627,000 | 66,354,000 |
| 0 | 0 | |
| LT Liab | 7,306,000 | 37,770,000 |
| Tot Curr Liab | 36,700,000 | 20,085,000 |
Jun 21 F |
Dec 20 I |
|
|---|---|---|
| EPS (ZARc) | 1052.9 | 558.4 |
| HEPS-C (ZARc) | 1204.3 | 571 |
| DPS (ZARc) | 262 | 0 |
| NAV PS (ZARc) | 14377.65 | 14535.38 |
| Ret on SH Fnd | 7.32 % | 7.68 % |
| Ret On Tot Ass | 11.93 % | 9.23 % |
| Next AGM date: Friday, 9 December 2022, unconfirmed |
| Interim results confirmed for release on Wednesday, 9 March 2022 |
Nature of business
Aspen Pharmacare Holdings Ltd, is a South African-based global specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The Group's Commercial Pharmaceuticals business comprises Sterile Focus and Regional Brands. Aspen has invested in strategically relevant manufacturing capacity and has capabilities across biological and chemical APIs, orals, liquids, topicals and steriles, at 23 manufacturing facilities on 6 continents.
Company email
rverster@aspenpharma.com
Company website
http://www.aspenpharma.com
Transfer secretary
JSE Investor Services (Pty) Ltd.
Company secretary
Riaan Verster
Postal address
PO Box 1587, Gallo Manor, 2052
Registered address
Building no 8, Healthcare Park, Woodlands Drive, Woodmead, Sandton, 2196
Company tel
011 239-6100
Company fax
Major shareholders
Government Employees Pension Fund, Saad, SB, Attridge, MG, Alexander Forbes Investments, Ceppawu Iinvestments (Pty) Ltd., Coronation Balanced Plus Fund, Vanguard Emerging Market Stock Index Fund (US), Coronation Top 20 Fund, Foord Balanced Fund, GIC Asset Management Pte Ltd.
You can cancel at any time.
